==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1017 which contains 9 entries.


Entry 1
(1) Primary information
ID1120
ThPP IDTh1017
Therapeutic Peptide/Protein NameSargramostim
SequenceAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQ view full sequnce in fasta
Functional ClassificationIb
Molecular Weight14434.5
Chemical FormulaC639H1006N168O196S8
Isoelectric Point5.05
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionSargramostim (127 residue glycoprotein) is a human recombinant granulocyte macrophage colony-stimulating factor expressed in yeast system. Substitution of Leu23 leads to a difference from native protein.
Indication/DiseaseUsed to treat cancer and in bone marrow transplant
PharmacodynamicsSargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy and recovering from acute myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism of ActionSargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor which stimulates a JAK2 STAT1/STAT3 signal transduction pathway which leads to the production of hemopoietic cells and neutrophils
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance420 mL/min/m2 [Normal people with liquid LEUKINE (IV)]
CategoriesImmunosuppressive Agents
Patents NumberCA1341150
Date of Issue05/12/00
Date of Expiry05/12/17
Drug InteractionN.A.
TargetGranulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan
Information of corresponding available drug in the market
Brand NameLeucomax
CompanyNovartis
Brand DiscriptionLeucomax contains a chemical which stimulates the colonies of white stem cells within the bone marrow causing the level of granulocytes in the blood to rise. Increasing the levels of granulocytes in the blood stream reduced the risk and severity of infe
Prescribed forUsed for reducing severe, life-threatening, or fatal infections after chemotherapy for acute myelogenous leukemia. It is also used to help increase the success of autologous bone marrow transplant and to help increase survival in patients who have bone ma
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceSolution
Route of AdministrationSubcutaneous and Intravenous infusion
Recommended DosageIn case of Intravenous Chemotherapy-induced neutropenia in adultS, 250 mcg/m2 daily for up to 42 days as required, to be given as IV infusion over 4 hr and in case of Intravenous Treatment and prevention of neutropenia in patients receiving myelosuppressivec chemotherapy.
ContraindicationN.A.
Side EffectsIt is common to have aching bones and joints for 2-3 days starting 1-2 days after the start of the injections. This is usually mild and is caused by the bone marrow working harder to make white cells. Occasionally it is more troublesome and pain killers are required.
Useful Linkhttp://www.cancernet.co.uk/leucomax.htm
PubMed ID25416452, 25270293, 15583528, 25270293, 27838641, 27783330, 27576783, 27619199, 27141384
3-D StructureTh1017 (View) or (Download)


Entry 2
(2) Primary information
ID1121
ThPP IDTh1017
Therapeutic Peptide/Protein NameSargramostim
SequenceAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQ view full sequnce in fasta
Functional ClassificationIb
Molecular Weight14434.5
Chemical FormulaC639H1006N168O196S8
Isoelectric Point5.05
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionSargramostim (127 residue glycoprotein) is a human recombinant granulocyte macrophage colony-stimulating factor expressed in yeast system. Substitution of Leu23 leads to a difference from native protein.
Indication/DiseaseUsed to treat cancer and in bone marrow transplant
PharmacodynamicsSargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy and recovering from acute myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism of ActionSargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor which stimulates a JAK2 STAT1/STAT3 signal transduction pathway which leads to the production of hemopoietic cells and neutrophils
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance431 mL/min/m2 [Normal people with lyophilized LEUKINE (IV)]
CategoriesImmunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsOccasionally irritation at the injection site.
Useful Linkhttp://www.igenericdrugs.com/?s=leucomax%20%28novartis%29
PubMed ID25416452, 25270293, 15583528, 25270293, 27838641, 27783330, 27576783, 27619199, 27141384
3-D StructureTh1017 (View) or (Download)


Entry 3
(3) Primary information
ID1122
ThPP IDTh1017
Therapeutic Peptide/Protein NameSargramostim
SequenceAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQ view full sequnce in fasta
Functional ClassificationIb
Molecular Weight14434.5
Chemical FormulaC639H1006N168O196S8
Isoelectric Point5.05
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionSargramostim (127 residue glycoprotein) is a human recombinant granulocyte macrophage colony-stimulating factor expressed in yeast system. Substitution of Leu23 leads to a difference from native protein.
Indication/DiseaseUsed to treat cancer and in bone marrow transplant
PharmacodynamicsSargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy and recovering from acute myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism of ActionSargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor which stimulates a JAK2 STAT1/STAT3 signal transduction pathway which leads to the production of hemopoietic cells and neutrophils
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance549 mL/min/m2 [Normal people with liquid LEUKINE (SC)]
CategoriesImmunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsVery rarely a disturbance in the liver function blood tests.
Useful LinkN.A.
PubMed ID25416452, 25270293, 15583528, 25270293, 27838641, 27783330, 27576783, 27619199, 27141384
3-D StructureTh1017 (View) or (Download)


Entry 4
(4) Primary information
ID1123
ThPP IDTh1017
Therapeutic Peptide/Protein NameSargramostim
SequenceAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQ view full sequnce in fasta
Functional ClassificationIb
Molecular Weight14434.5
Chemical FormulaC639H1006N168O196S8
Isoelectric Point5.05
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionSargramostim (127 residue glycoprotein) is a human recombinant granulocyte macrophage colony-stimulating factor expressed in yeast system. Substitution of Leu23 leads to a difference from native protein.
Indication/DiseaseUsed to treat cancer and in bone marrow transplant
PharmacodynamicsSargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy and recovering from acute myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism of ActionSargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor which stimulates a JAK2 STAT1/STAT3 signal transduction pathway which leads to the production of hemopoietic cells and neutrophils
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance529 mL/min/m2 [Normal people with lyophilized LEUKINE (SC)]
CategoriesImmunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsRare mild flu like symptom, headache, malaise, rigors & nausea.
Useful LinkN.A.
PubMed ID25416452, 25270293, 15583528, 25270293, 27838641, 27783330, 27576783, 27619199, 27141384
3-D StructureTh1017 (View) or (Download)


Entry 5
(5) Primary information
ID1124
ThPP IDTh1017
Therapeutic Peptide/Protein NameSargramostim
SequenceAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQ view full sequnce in fasta
Functional ClassificationIb
Molecular Weight14434.5
Chemical FormulaC639H1006N168O196S8
Isoelectric Point5.05
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionSargramostim (127 residue glycoprotein) is a human recombinant granulocyte macrophage colony-stimulating factor expressed in yeast system. Substitution of Leu23 leads to a difference from native protein.
Indication/DiseaseUsed to treat cancer and in bone marrow transplant
PharmacodynamicsSargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy and recovering from acute myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism of ActionSargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor which stimulates a JAK2 STAT1/STAT3 signal transduction pathway which leads to the production of hemopoietic cells and neutrophils
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesImmunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsRare mild itching and occasional skin rash.
Useful LinkN.A.
PubMed ID25416452, 25270293, 15583528, 25270293, 27838641, 27783330, 27576783, 27619199, 27141384
3-D StructureTh1017 (View) or (Download)


Entry 6
(6) Primary information
ID1125
ThPP IDTh1017
Therapeutic Peptide/Protein NameSargramostim
SequenceAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQ view full sequnce in fasta
Functional ClassificationIb
Molecular Weight14434.5
Chemical FormulaC639H1006N168O196S8
Isoelectric Point5.05
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionSargramostim (127 residue glycoprotein) is a human recombinant granulocyte macrophage colony-stimulating factor expressed in yeast system. Substitution of Leu23 leads to a difference from native protein.
Indication/DiseaseUsed to treat cancer and in bone marrow transplant
PharmacodynamicsSargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy and recovering from acute myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism of ActionSargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor which stimulates a JAK2 STAT1/STAT3 signal transduction pathway which leads to the production of hemopoietic cells and neutrophils
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesImmunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameLeukine
CompanyBerlex Laboratories Inc
Brand DiscriptionLEUKINE is a recombinant human granulocyte macrophage colony stimulating factor produced by recombinant DNA technology in a yeast expression system. GM-CSF is a hematopoietic growth stimulating factor which stimulates proliferation and differentiation of
Prescribed forLeukine is used to increase white blood cells and help prevent serious infection in conditions such as leukemia, bone marrow transplant, and pre-chemotherapy blood cell collection. Leukine is used for adults who are at least 55 years old.
Chemical NameN.A.
FormulationThe liquid vial and reconstituted lyophilized vial both contain 40 mg/mL mannitol, USP; 10 mg/mL sucrose, NF; and 1.2 mg/mL tromethamine, USP, as excipients
Physcial AppearanceSterile, preserved (1.1% benzyl alcohol), injectable solution (500 mcg/mL) and also as sterile, white, preservative free lyophilized powder (250 mcg) that requires reconstitution with 1 mL Sterile water for Injection
Route of AdministrationSubcutaneous Injection (Subcutaneous) or Intraveno
Recommended DosageIn Neutrophil Recovery, Chemotherapy in Acute Myelogenous Leukemia, the recommended dose is 250 mcg/m2/day, administered intravenously over a 4 hour period starting approximately on day 11 or four days following the completion of induction chemotherapy, , if the day 10 bone marrow is hypoplastic with <5% blasts.
ContraindicationAllergy
Side EffectsHigh fever, chills, sore throat, stuffy nose, flu symptoms; white patches or sores inside your mouth or on your lips; easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin; swelling, rapid weight gain, chest pain, fast or uneven heart rate, weakness or fainting, black-bloody or tarry stools, coughing up blood, painful urination, clay-colored stools, jaundice, breathing problems and problems with vision, speech, balance or memory.
Useful Linkhttp://www.drugs.com/leukine.html
PubMed ID25416452, 25270293, 15583528, 25270293, 27838641, 27783330, 27576783, 27619199, 27141384
3-D StructureTh1017 (View) or (Download)


Entry 7
(7) Primary information
ID1126
ThPP IDTh1017
Therapeutic Peptide/Protein NameSargramostim
SequenceAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQ view full sequnce in fasta
Functional ClassificationIb
Molecular Weight14434.5
Chemical FormulaC639H1006N168O196S8
Isoelectric Point5.05
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionSargramostim (127 residue glycoprotein) is a human recombinant granulocyte macrophage colony-stimulating factor expressed in yeast system. Substitution of Leu23 leads to a difference from native protein.
Indication/DiseaseUsed to treat cancer and in bone marrow transplant
PharmacodynamicsSargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy and recovering from acute myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism of ActionSargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor which stimulates a JAK2 STAT1/STAT3 signal transduction pathway which leads to the production of hemopoietic cells and neutrophils
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesImmunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageMobilization of Peripheral Blood Progenitor Cells, the recommended dose is 250 mcg/m2/day administered IV over 24 hours or SC once daily.
ContraindicationN.A.
Side EffectsBlack, bloody, or tarry stools; coughing up blood or vomit that looks like coffee grounds; painful or difficult urination; dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); breathing problems; or problems with vision, speech, balance or memory.
Useful Linkhttp://www.drugs.com/drug-interactions/sargramostim,leukine-index.html
PubMed ID25416452, 25270293, 15583528, 25270293, 27838641, 27783330, 27576783, 27619199, 27141384
3-D StructureTh1017 (View) or (Download)


Entry 8
(8) Primary information
ID1127
ThPP IDTh1017
Therapeutic Peptide/Protein NameSargramostim
SequenceAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQ view full sequnce in fasta
Functional ClassificationIb
Molecular Weight14434.5
Chemical FormulaC639H1006N168O196S8
Isoelectric Point5.05
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionSargramostim (127 residue glycoprotein) is a human recombinant granulocyte macrophage colony-stimulating factor expressed in yeast system. Substitution of Leu23 leads to a difference from native protein.
Indication/DiseaseUsed to treat cancer and in bone marrow transplant
PharmacodynamicsSargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy and recovering from acute myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism of ActionSargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor which stimulates a JAK2 STAT1/STAT3 signal transduction pathway which leads to the production of hemopoietic cells and neutrophils
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesImmunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosagePost Peripheral Blood Progenitor Cell Transplantation, the recommended dose is 250 mcg/m2/day administered IV over 24 hours or SC once daily beginning immediately following infusion of progenitor cells and continuing until an ANC>1500 cells/mm3 for three consecutive days is attained.
ContraindicationN.A.
Side EffectsNausea, stomach pain, vomiting, diarrhea, loss of appetite; tired feeling; hair loss; weight loss; headache.
Useful Linkhttp://www.drugs.com/drug-interactions/sargramostim,leukine-index.html
PubMed ID25416452, 25270293, 15583528, 25270293, 27838641, 27783330, 27576783, 27619199, 27141384
3-D StructureTh1017 (View) or (Download)


Entry 9
(9) Primary information
ID1128
ThPP IDTh1017
Therapeutic Peptide/Protein NameSargramostim
SequenceAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQ view full sequnce in fasta
Functional ClassificationIb
Molecular Weight14434.5
Chemical FormulaC639H1006N168O196S8
Isoelectric Point5.05
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionSargramostim (127 residue glycoprotein) is a human recombinant granulocyte macrophage colony-stimulating factor expressed in yeast system. Substitution of Leu23 leads to a difference from native protein.
Indication/DiseaseUsed to treat cancer and in bone marrow transplant
PharmacodynamicsSargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy and recovering from acute myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism of ActionSargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor which stimulates a JAK2 STAT1/STAT3 signal transduction pathway which leads to the production of hemopoietic cells and neutrophils
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesImmunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageMyeloid Reconstitution After Autologous or Allogeneic Bone Marrow Transplantation, the recommended dose is 250 mcg/m2/day administered IV over a 2-hour period beginning two to four hours after bone marrow infusion, and not less than 24 hours after the last dose of chemotherapy or radiotherapy.
ContraindicationN.A.
Side EffectsMild skin rash or itching; bone pain; joint or muscle pain; or redness, swelling, or irritation where the injection was given.
Useful Linkhttp://www.rxlist.com/leukine-drug.htm
PubMed ID25416452, 25270293, 15583528, 25270293, 27838641, 27783330, 27576783, 27619199, 27141384
3-D StructureTh1017 (View) or (Download)